Described herein are orally-bioavailable nucleoside analogs and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of coronavirus infections, including SARS-CoV-2 infection.

Described herein are orally-bioavailable nucleoside analogs and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of coronavirus infections, including SARS-CoV-2 infection.

Antimicrobial compounds and compositions of Formulas (V), (VI), (VII), (VIII), and (IX), and methods of use are disclosed.

Antimicrobial compounds and compositions of Formulas (V), (VI), (VII), (VIII), and (IX), and methods of use are disclosed.

The present invention relates to compounds comprising a salt of a diphosphate phosphoramidate of a nucleoside drug, e.g. clofarabine. The compounds are useful in the treatment of cancer, e.g. leukemia.

The present invention relates to compounds comprising a salt of a diphosphate phosphoramidate of a nucleoside drug, e.g. clofarabine. The compounds are useful in the treatment of cancer, e.g. leukemia.

The invention is directed to a method for production of a deoxynucleotide triphosphate according to general formula (7)

##STR00001## wherein B is a nucleobase and R is an alkyl group having 1 to 4 carbon atoms and n is an integer from 1 to 10 by reaction of reaction precursor of compound 6

##STR00002## wherein R.sub.1, R.sub.2 and R.sub.3 are independently H, O-Alkyl with alkyl residues having 1 to 4 carbon atoms or halogen and n is an integer from 1 to 10 with dialkyl(alkylthio)sulfonium salt (8B)

##STR00003## wherein R.sub.4, R.sub.5 R.sub.6 are independently alkyl residues having 1 to 4 carbon atoms and X is selected from the group consisting of BF.sub.4.sup.−, F.sup.−, Cl.sup.−, Br.sup.−, I.sup.−, SO.sub.4.sup.2−, SO.sub.3.sup.2− in aqueous solution having a pH between 3 and 7.

The invention is directed to a method for production of a deoxynucleotide triphosphate according to general formula (7)

##STR00001## wherein B is a nucleobase and R is an alkyl group having 1 to 4 carbon atoms and n is an integer from 1 to 10 by reaction of reaction precursor of compound 6

##STR00002## wherein R.sub.1, R.sub.2 and R.sub.3 are independently H, O-Alkyl with alkyl residues having 1 to 4 carbon atoms or halogen and n is an integer from 1 to 10 with dialkyl(alkylthio)sulfonium salt (8B)

##STR00003## wherein R.sub.4, R.sub.5 R.sub.6 are independently alkyl residues having 1 to 4 carbon atoms and X is selected from the group consisting of BF.sub.4.sup.−, F.sup.−, Cl.sup.−, Br.sup.−, I.sup.−, SO.sub.4.sup.2−, SO.sub.3.sup.2− in aqueous solution having a pH between 3 and 7.

A modified cytidine compound, that is, an aminooxy group is modified at the 4-position of a cytidine pyrimidine ring to produce derivative cytidine and nucleic acid containing the derivative cytidine, such as RNA. The expression level of the nucleic acid containing the modified cytidine, in particular mRNA, in the body is significantly improved.

A modified cytidine compound, that is, an aminooxy group is modified at the 4-position of a cytidine pyrimidine ring to produce derivative cytidine and nucleic acid containing the derivative cytidine, such as RNA. The expression level of the nucleic acid containing the modified cytidine, in particular mRNA, in the body is significantly improved.